Scarica l'app Stockscreener
33.44
0.12%
-0.128
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$33.57
Aprire:
$33.94
Volume 24 ore:
626.18K
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.83B
Reddito:
$11.13M
Utile/perdita netta:
$-81.99M
Rapporto P/E:
-18.59
EPS:
-1.7988
Flusso di cassa netto:
$-68.38M
1 W Prestazione:
+29.86%
1M Prestazione:
+41.66%
6M Prestazione:
+427.20%
1 anno Prestazione:
+156.54%
Intervallo 1D:
$32.25
$34.21
Intervallo di 1 settimana:
$25.08
$36.49
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
33.55 | 1.83B | 11.13M | -81.99M | -68.38M | -1.7988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.94 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.71 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.11 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.00 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data - GlobeNewswire
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s cell therapy deramiocel - The Pharma Letter
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge - Markets Mojo
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
FDA resumes review of Capricor’s Deramiocel for DMD treatment By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026 - Meyka
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA - simplywall.st
Capricor Therapeutics (CAPR) Surges as FDA Reviews Key Therapy - GuruFocus
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Sahm
Capricor Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review - marketscreener.com
Capricor Therapeutics Sees Surge in Trading Volume - National Today
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Jones Trading reiterates Capricor stock Buy on FDA review resumption By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (C - GuruFocus
Capricor Advances Deramiocel BLA Review for Duchenne DMD - TipRanks
Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Capricor resumes FDA BLA review for Deramiocel; PDUFA date set for Aug 22, 2026 - TradingView
FDA sets new Deramiocel PDUFA date for Capricor (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga
FDA Resumes Review of Capricor Therapeutics' (CAPR) Deramiocel A - GuruFocus
Capricorgains FDA reviews rejected cell therapy (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA - Bitget
Capricor Therapeutics, Inc. resumes Deramiocel BLA review as FDA sets August 22, 2026 deadline - Traders Union
Capricor Therapeutics Announces Resumption of FDA BLA Review for Deramiocel in Duchenne Muscular Dystrophy Following Positive Phase 3 Results - Quiver Quantitative
FDA resumes review of Duchenne drug Deramiocel, sets Aug. 22 deadline - Stock Titan
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy - Yahoo Finance
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpStill a Buy? - MarketBeat
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds - TechStock²
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - The Manila Times
Capricor Therapeutics to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Quiver Quantitative
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway - Sahm
Capricor Therapeutics Stock Pre-Market (+12%): 91-Day Insider Lock-Up Period Expires - Trefis
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
Capricor Therapeutics Poised for Breakthrough as HOPE-3 Trial Results Loom - timothysykes.com
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2%Here's What Happened - MarketBeat
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - Stocktwits
HOPE On The Horizon: Capricor To Present Deramiocel Data At The MDA Conference - RTTNews
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):